Skip to content
HowShorted

GeneDx Holdings Corp. Class A short interest in 2024

In 2024, GeneDx Holdings Corp. Class A's disclosed short interest ran from 3.83% of shares outstanding on 12 Jan 2024 to 7.57% on 31 Dec 2024, a change of +3.74 percentage points. The year's high was 9.48% on 31 Oct 2024 and its low 3.83% on 12 Jan 2024, averaging 6.13% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.97 days on 15 Feb 2024. Full history: GeneDx Holdings Corp. Class A.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for GeneDx Holdings Corp. Class A in 2024

2024 in figures

Start of year
3.83% (12 Jan 2024)
End of year
7.57% (31 Dec 2024)
Change
+3.74 pp
High
9.48% (31 Oct 2024)
Low
3.83% (12 Jan 2024)
Average
6.13%
Highest days to cover
9.97 (15 Feb 2024)
SEC filings marked
9

Every report in 2024

GeneDx Holdings Corp. Class A short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20243.83%2.29results (8-K)
31 Jan 20244.10%3.29
15 Feb 20244.66%9.97
29 Feb 20244.25%3.31results (8-K), 10-K filed
15 Mar 20244.07%5.09
28 Mar 20244.25%5.06
15 Apr 20244.13%7.40
30 Apr 20244.44%1.4510-Q filed, results (8-K)
15 May 20244.47%1.34
31 May 20244.02%3.20
14 Jun 20244.30%3.28
28 Jun 20244.68%2.69
15 Jul 20246.18%4.07
31 Jul 20247.06%3.4510-Q filed, results (8-K)
15 Aug 20247.60%5.13
30 Aug 20248.12%6.34
13 Sep 20248.23%6.09
30 Sep 20248.19%4.91
15 Oct 20248.93%3.73
31 Oct 20249.48%3.2510-Q filed, results (8-K)
15 Nov 20248.51%3.54
29 Nov 20248.31%4.57
13 Dec 20247.82%4.34
31 Dec 20247.57%4.10

See also: GeneDx Holdings Corp. Class A's full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.